One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Affimed N.V. logo
Affimed N.V. AFMD
report update icon

Quarterly report 2024-Q2
added 05-23-2026

Affimed N.V. Income Statement 2023-2011 | AFMD

Brief overview of revenue and earnings at Affimed N.V.

The conclusions below are based on five years of reported results. According to figures from Affimed N.V., revenue changed from 23.7 million euros to 8.3 million euros over five years. Overall revenue changed by −65.1%, equal to an annualized rate of about −19%. Sales followed a declining trajectory over the five years.

EBITDA was −19.5 million euros at the beginning and −107 million euros at the end of the period (−446%). EBITDA lagged revenue, showing weaker operating momentum. At the operating-margin level, the figure shifted from −82.3% to −1289%. Operating return per unit of revenue declined.

The final result was −19.5 million euros initially and −106 million euros in the final year. The period ended with a larger loss than it began with.

Summary assessment

The current trajectory does not yet confirm a sustainable recovery. The overall view is constrained by a narrow EBITDA buffer, a declining EBITDA margin and declining net profitability. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.

Annual Income Statement Affimed N.V.

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - 527 M 473 M 152 M 212 M 93 M 66.5 M 90.8 M 136 M - - -

Shares

- - 120 M 83.5 M 64.2 M 60.5 M 43.7 M 33.3 M 28.5 M 24 M - - -

Historical Prices

- - 4.41 5.67 2.36 3.51 2.12 2 3.19 6.17 - - -

Net Income

-106 M -86 M -57.5 M -41.4 M -32.4 M -19.5 M -30.2 M -32.2 M -20.2 M -260 K -26.1 M -14.3 M -

Revenue

8.28 M 41.4 M 40.4 M 28.4 M 21.4 M 23.7 M 2.01 M 6.31 M 7.56 M 3.38 M 5.09 M 1.17 M -

Gross Profit

- - - - 19.8 M 22.6 M 1.02 M 5.29 M 6.66 M 2.54 M 4.38 M 620 K -

Operating Income

-107 M -88.1 M -64 M -34.7 M -32.4 M -19.5 M -27.3 M -32 M -21.3 M - - - -

EBITDA

-107 M -88.1 M -64 M -34.7 M -32.4 M -19.5 M -27.3 M -32 M -21.3 M -7.74 M -15.3 M -9.99 M -

Operating Expenses

- - - - 54 M 43.3 M 29.3 M 38.4 M 28.9 M 11.6 M 20.8 M 11.6 M -

General and Administrative Expenses

24.7 M 32.1 M 24.2 M 13.7 M 10.3 M 9.64 M 7.99 M 8.32 M 7.55 M 2.35 M 7.05 M 3.05 M -

All numbers in EUR currency

Quarterly Income Statement Affimed N.V.

2024-Q2 2023-Q4 2023-Q3 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

15.3 M - - 149 M - - 147 M - 120 M - 120 M - 83.5 M - 79.2 M - 64.2 M - 62.4 M - 60.5 M - 62.4 M - 43.7 M - - - 33.3 M - - - 28.5 M - - - - - - - - - - - - - - - - - - -

Net Income

-15.5 M -106 M - -29.4 M - - -19.4 M - -57.5 M - -18.8 M - -41.4 M - -12.2 M - -32.4 M - -10.3 M - -19.5 M - -8.01 M - -30.2 M - - - -32.2 M - - - -20.2 M - - - - - - - - - - - - - - - - - - -

Revenue

154 K 8.28 M - 1.39 M - - 7.3 M - 40.4 M - 9.71 M - 28.4 M - 2.93 M - 21.4 M - 4.01 M - 23.7 M - 150 K - 2.01 M - - - 6.31 M - - - 7.56 M - - - - - - - - - - - - - - - - - - -

Operating Income

-15.6 M -107 M - -29.4 M - - -21.7 M - -64 M - -17.2 M - -34.7 M - -11.3 M - -32.4 M - -9.68 M - -19.5 M - -9.11 M - -27.3 M - - - -32 M - - - -21.3 M - - - - - - - - - - - - - - - - - - -

EBITDA

-15.6 M -107 M - -29.4 M - - -21.7 M - -64 M - -17.2 M - -34.7 M - -11.3 M - -32.4 M - -9.68 M - -19.5 M - -9.11 M - -27.3 M - - - -32 M - - - -21.3 M - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

4.04 M 24.7 M - 6.28 M - - 8.37 M - 24.2 M - 5.44 M - 13.7 M - 2.61 M - 10.3 M - 2.34 M - 9.64 M - 2.16 M - 7.99 M - - - 8.32 M - - - 7.55 M - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

The income statement is one of the three key financial reports of a company Affimed N.V. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 4.2 -0.36 % $ 651 M usaUSA
AbbVie AbbVie
ABBV
$ 294.72 0.32 % $ 521 B usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.78 0.89 % $ 296 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 316.97 4.77 % $ 24.7 B usaUSA
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
- -60.05 % $ 125 K usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 62.89 0.18 % $ 128 B usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 58.59 4.29 % $ 7.04 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 159.75 5.35 % $ 20.9 B usaUSA
Amgen Amgen
AMGN
$ 467.97 0.59 % $ 252 B usaUSA
Orgenesis Orgenesis
ORGS
- -33.86 % $ 61.2 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc
JAZZ
$ 248.31 1.17 % $ 15.1 B irlandaIrlanda
Johnson & Johnson Johnson & Johnson
JNJ
$ 280.31 -0.17 % $ 675 B usaUSA
Kala Pharmaceuticals Kala Pharmaceuticals
KALA
$ 0.17 0.64 % $ 1.39 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 1.49 -1.97 % $ 3.67 B israelIsrael
Sage Therapeutics Sage Therapeutics
SAGE
- - $ 527 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.59 -2.76 % $ 2.62 M israelIsrael
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
$ 1.13 8.17 % $ 260 M usaUSA
Paratek Pharmaceuticals Paratek Pharmaceuticals
PRTK
- - $ 121 M usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
- - $ 58.1 M usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 2.9 -3.5 % $ 240 M usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
$ 1 437.4 0.36 % $ 1.29 T usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.09 -0.24 % $ 195 M israelIsrael
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
GeoVax Labs GeoVax Labs
GOVX
$ 2.13 -20.4 % $ 2.04 M usaUSA
Unity Biotechnology Unity Biotechnology
UBX
- -33.41 % $ 3.37 M usaUSA
MediciNova MediciNova
MNOV
$ 1.41 0.36 % $ 69.2 M usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Seelos Therapeutics Seelos Therapeutics
SEEL
- -47.76 % $ 6.27 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 30.18 -1.53 % $ 2 B usaUSA
Moderna Moderna
MRNA
$ 248.62 -0.88 % $ 96.7 B usaUSA